Lexicon Pharmaceuticals, Inc. (LXRX)
| Market Cap | 892.83M +271.9% |
| Revenue (ttm) | 69.64M +123.1% |
| Net Income | -26.09M |
| EPS | -0.07 |
| Shares Out | 444.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,925,687 |
| Open | 2.040 |
| Previous Close | 2.040 |
| Day's Range | 1.975 - 2.100 |
| 52-Week Range | 0.703 - 2.530 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 3.77 (+87.56%) |
| Earnings Date | Aug 5, 2026 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart fail... [Read more]
Financial Performance
In 2025, Lexicon Pharmaceuticals's revenue was $49.80 million, an increase of 60.24% compared to the previous year's $31.08 million. Losses were -$50.34 million, -74.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price target is $3.77, which is an increase of 87.56% from the latest price.
News
Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a focused cardiometabolic pipeline, with key milestones including imminent completion of a pivotal HCM trial, FDA resubmission for type 1 diabetes, and strategic partnerships for obesity and pain assets. Unique clinical positioning and strong financial planning support future launches.
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductio...
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Gl...
Lexicon Pharmaceuticals Slides: Investor presentation
Lexicon Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Lexicon Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The conference highlighted late-stage and early-stage pipeline progress, including sotagliflozin’s regulatory path in Type 1 Diabetes and HCM, a strong financial position with recent capital raises, and strategic partnerships such as with Novo Nordisk for LX9851. Key milestones are expected through Q1 2027.
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. W...
Lexicon price target raised to $3.10 from $2.30 at Citi
Citi raised the firm’s price target on Lexicon (LXRX) to $3.10 from $2.30 and keeps a Buy rating on the shares.
Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw a sharp revenue increase from milestone payments and reduced net loss, with strong cash reserves and lower expenses. Key pipeline programs advanced toward major regulatory milestones, and financial flexibility was enhanced through a new debt facility.
Lexicon Pharmaceuticals Earnings release: Q1 2026
Lexicon Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Lexicon Pharmaceuticals Slides: Q1 2026
Lexicon Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Lexicon Pharmaceuticals Quarterly report: Q1 2026
Lexicon Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 i...
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) th...
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May...
Lexicon to present data at AAN annual meeting on Progress Phase 2b study
Lexicon (LXRX) Pharmaceuticals announced that results from its Progress Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain, DPNP, supporting the selection of pilavapadin 10 mg as th...
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analys...
Lexicon, Novo Nordisk announce initiation of LX9851 study
Lexicon (LXRX) and Novo Nordisk (NVO) announced that Novo Nordisk has initiated a Phase 1 study with LX9851, an oral non-incretin development candidate. In March 2025, Lexicon signed an exclusive…
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon Pharmaceuticals Proxy statement: Proxy Filing
Lexicon Pharmaceuticals filed a proxy statement on March 16, 2026, providing details for shareholder voting and corporate governance matters.
Lexicon Pharmaceuticals Proxy statement: Proxy Filing
Lexicon Pharmaceuticals filed a proxy statement on March 16, 2026, providing details for shareholder voting and corporate governance matters.
Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The company is advancing late-stage programs in HCM, type 1 diabetes, and neuropathic pain, with strong regulatory engagement and strategic partnerships. Key milestones include imminent Phase 3 data, NDA resubmission, and new obesity drug trials with Novo Nordisk.
Lexicon announces results from post hoc analysis on data of sotagliflozin
Lexicon (LXRX) Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people…
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kid...
Lexicon price target raised to $2.30 from $2.10 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Lexicon (LXRX) to $2.30 from $2.10 and keeps a Buy rating on the shares.